Sunday 18 October 2026
Export PYPD’s income statement to Excel — free account
PolyPid Ltd.
PYPD Healthcare Biotechnology
In the quarter to June 2026, EPS grew 55.1%, free cash flow fell 65.0% and total debt fell 88.4%, each against the same quarter a year earlier.
4.75
0.15
−3.06%
Follow PYPD
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
10.75 | 5.57 | 2.18 | 10.62 | 16.41 | 4.31 | 1.66 | 0.83 | 1.31 | 1.97 |
Net Debt/EBITDA |
1.75 | 1.32 | 0.42 | 1.53 | 1.78 | 0.78 | 0.04 | (0.23) | 0.32 | 0.39 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 44.66% | 67.54% | 29.43% | 4.43% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.99 | (4.95) | 0.97 | 0.09 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.70 | 0.21 | (2.82) | 2.51 | 0.50 | 0.76 | 0.87 | 0.72 | 0.76 | 0.82 |
Capex/Depreciation |
0.00 | 0.00 | (7.48) | (0.93) | (0.77) | (2.37) | (1.03) | (0.11) | (0.05) | (0.14) |
Interest Coverage |
(114.63) | (260.38) | — | — | — | — | — | — | — | — |
| 22.84% | 96.48% | (6.95%) | 8.16% | 577.80% | (78.36%) | (189.32%) | (1,278.60%) | (1,038.73%) | (366.29%) | |
| (66.32%) | (614.88%) | 35.09% | (28.63%) | (78.31%) | (70.95%) | (112.69%) | (115.45%) | (142.99%) | (143.79%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (58.83%) | (802.55%) | (562.36%) | (533.88%) | 0.00% | 0.00% |
Return on Tangible Assets |
(80.45%) | (323.32%) | 56.17% | (22.32%) | (85.47%) | (120.02%) | (265.70%) | (372.77%) | (291.18%) | (271.57%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(0.73) | (0.93) | (1,056.26) | (975.24) | (70.13) | (56.21) | (55.72) | (12.41) | (3.73) | (1.72) |
Cash per Share |
1.34 | 1.35 | 403.64 | 1,442.99 | 140.60 | 52.29 | 20.24 | 3.99 | 2.67 | 0.80 |
Shareholders Equity per Share |
0.76 | (2.16) | (4,369.52) | 998.98 | 228.07 | 57.68 | 9.00 | (1.49) | 1.30 | 0.67 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.76 | (2.16) | (4,369.52) | 998.98 | 228.07 | 57.68 | 9.00 | (1.49) | 1.30 | 0.67 |
Free Cash Flow |
(9.73) | (12.31) | (19.75) | (18.24) | (22.38) | (35.04) | (36.08) | (17.43) | (22.04) | (28.09) |
Working Capital |
16.56 | 15.37 | 4.35 | 24.82 | 44.32 | 26.74 | 5.64 | (1.22) | 3.89 | 7.49 |
Capital Expenditures |
(0.54) | (1.88) | (3.07) | (0.88) | (0.78) | (2.65) | (1.77) | (0.20) | (0.08) | (0.21) |
Net Current Asset Value |
9.08 | (32.92) | (88.16) | 12.33 | 44.13 | 26.54 | (5.95) | (11.40) | (0.96) | 3.89 |
| Other line items | ||||||||||
Quick Ratio |
10.47 | 5.34 | 2.05 | 10.46 | 15.59 | 4.04 | 1.53 | 0.77 | 1.25 | 1.70 |
Depreciation/Fixed assets |
0.15 | 0.07 | 0.07 | 0.15 | 0.17 | 0.13 | 0.19 | 0.24 | 0.27 | 0.29 |
Cash ROIC |
(34.99%) | 114.80% | 26.63% | (39.94%) | (19.02%) | (51.11%) | (118.18%) | (125.46%) | (71.29%) | (111.97%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.73) | (0.93) | (891.87) | (928.24) | (67.68) | (51.95) | (52.99) | (12.27) | (3.71) | (1.70) |
Capex per Share |
0.00 | 0.00 | (164.38) | (47.01) | (2.45) | (4.26) | (2.73) | (0.14) | (0.01) | (0.01) |
Average Receivables |
0.03 | 0.03 | 0.03 | 0.02 | 0.02 | — | — | — | — | — |
Average Payables |
— | — | 1.36 | 1.36 | 1.28 | 2.56 | 2.64 | 0.96 | 1.59 | 2.63 |
Average Assets |
21.11 | 9.62 | 16.86 | 24.12 | 54.80 | 60.04 | 35.10 | 20.67 | 20.30 | 23.76 |
Average Common Equity |
(61.30) | (61.30) | (85.18) | (84.67) | (7.43) | 54.37 | 20.89 | 1.87 | 2.79 | 9.33 |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates